390 related articles for article (PubMed ID: 21174061)
21. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
22. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of CD133(+) human colon cancer SW620 cells.
Kawamoto H; Yuasa T; Kubota Y; Seita M; Sasamoto H; Shahid JM; Hayashi T; Nakahara H; Hassan R; Iwamuro M; Kondo E; Nakaji S; Tanaka N; Kobayashi N
Cell Transplant; 2010; 19(6):857-64. PubMed ID: 20587144
[TBL] [Abstract][Full Text] [Related]
24. Small nucleolar RNA signatures of lung tumor-initiating cells.
Mannoor K; Shen J; Liao J; Liu Z; Jiang F
Mol Cancer; 2014 May; 13():104. PubMed ID: 24886050
[TBL] [Abstract][Full Text] [Related]
25. The study of the tumor stem cell properties of CD133+CD44+ cells in the human lung adenocarcinoma cell line A549.
Zhang HZ; Lin XG; Hua P; Wang M; Ao X; Xiong LH; Wu C; Guo JJ
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1350-8. PubMed ID: 20937222
[TBL] [Abstract][Full Text] [Related]
26. Identification and expansion of the tumorigenic lung cancer stem cell population.
Eramo A; Lotti F; Sette G; Pilozzi E; Biffoni M; Di Virgilio A; Conticello C; Ruco L; Peschle C; De Maria R
Cell Death Differ; 2008 Mar; 15(3):504-14. PubMed ID: 18049477
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
28. CD133+ cancer stem cells in lung cancer.
Wang S; Xu ZY; Wang LF; Su W
Front Biosci (Landmark Ed); 2013 Jan; 18(2):447-53. PubMed ID: 23276935
[TBL] [Abstract][Full Text] [Related]
29. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
30. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
[TBL] [Abstract][Full Text] [Related]
31. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
[TBL] [Abstract][Full Text] [Related]
32. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
33. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
35. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells.
Karimi-Busheri F; Zadorozhny V; Li T; Lin H; Shawler DL; Fakhrai H
J Stem Cells; 2011; 6(1):9-20. PubMed ID: 22997842
[TBL] [Abstract][Full Text] [Related]
36. [Experimental investigation of CD133 as a putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Dec; 41(12):940-4. PubMed ID: 17345710
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
38. Cytometric profiling of CD133+ cells in human colon
carcinoma cell lines identifies a common core phenotype
and cell type-specific mosaics.
Gemei M; Di Noto R; Mirabelli P; Del Vecchio L
Int J Biol Markers; 2013 Sep; 28(3):267-73. PubMed ID: 23709346
[TBL] [Abstract][Full Text] [Related]
39. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
40. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
